BRPI0613771A2 - derivado de heterociclideno acetamida - Google Patents

derivado de heterociclideno acetamida

Info

Publication number
BRPI0613771A2
BRPI0613771A2 BRPI0613771-7A BRPI0613771A BRPI0613771A2 BR PI0613771 A2 BRPI0613771 A2 BR PI0613771A2 BR PI0613771 A BRPI0613771 A BR PI0613771A BR PI0613771 A2 BRPI0613771 A2 BR PI0613771A2
Authority
BR
Brazil
Prior art keywords
group
compound
salt
isomer
solvate
Prior art date
Application number
BRPI0613771-7A
Other languages
English (en)
Inventor
Hideharu Uchida
Naoto Kosuga
Tsutomu Satoh
Daido Hotta
Tomoyuki Kamino
Yoshitaka Maeda
Ken-Ichi Amano
Yasushige Akada
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of BRPI0613771A2 publication Critical patent/BRPI0613771A2/pt
Publication of BRPI0613771B1 publication Critical patent/BRPI0613771B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

DERIVADO DE HETEROCICLIDENO ACETAMIDA. Um composto representado pela fórmula (I') (em que m, n, e p cada um representa O a 2; q representa O ou 1; R¹ representa halogênio, um grupo hidrocarboneto, um grupo heterocíclico, um grupo alcoxi, um grupo alcoxicarbonil, um grupo sulfamoil, um grupo CN, um grupo NO~ 2~, ou outros; R² representa halogênio, amino, um grupo hidrocarboneto, um grupo heterocíclico aromático, ou um grupo oxo; X~ 1~ representa O, -NR³-, ou -S(O)r-; X~ 2~ representa um grupo metileno, O, -NR³-, ou -S(O)r-; Q' representa um grupo heteroaril, um grupo heteroarilalquil, um grupo aril substituído, ou um grupo aralquil; Porção de ciclo representa um anel aril ou um anel heteroaril; e a linha ondulada representa um E-isómero ou um Z-isómero), um sal do composto, ou um solvato do composto ou o sal. Uma composição farmacêutica e um Antagonista de receptor tipo I potencial de receptor transitório (TRPV1) cada um contendo, como um ingrediente ativo, pelo menos um do composto, um sal do composto e um solvato do composto ou o sal.
BRPI0613771-7A 2005-07-22 2006-07-24 Composto derivado de heterociclideno acetamida, composição farmacêutica e antagonista de receptor de tipo i vaniloide com potencial de receptor transitório (trpv1) BRPI0613771B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2005213534 2005-07-22
JP2005-213534 2005-07-22
JP2005330890 2005-11-15
JP2005-330890 2005-11-15
JP2006045985 2006-02-22
JP2006-045985 2006-02-22
PCT/IB2006/002016 WO2007010383A1 (ja) 2005-07-22 2006-07-24 新規なヘテロシクリデンアセトアミド誘導体

Publications (2)

Publication Number Publication Date
BRPI0613771A2 true BRPI0613771A2 (pt) 2009-05-19
BRPI0613771B1 BRPI0613771B1 (pt) 2021-11-23

Family

ID=37668470

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0613771-7A BRPI0613771B1 (pt) 2005-07-22 2006-07-24 Composto derivado de heterociclideno acetamida, composição farmacêutica e antagonista de receptor de tipo i vaniloide com potencial de receptor transitório (trpv1)

Country Status (14)

Country Link
US (2) US7910751B2 (pt)
EP (1) EP1908753B1 (pt)
JP (2) JP4754566B2 (pt)
KR (2) KR101136183B1 (pt)
AU (1) AU2006271297C1 (pt)
BR (1) BRPI0613771B1 (pt)
CA (1) CA2616079C (pt)
CR (1) CR9660A (pt)
EC (1) ECSP088129A (pt)
ES (1) ES2531621T3 (pt)
NO (1) NO341962B1 (pt)
NZ (1) NZ565080A (pt)
PT (1) PT1908753E (pt)
WO (1) WO2007010383A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2616079C (en) 2005-07-22 2012-09-25 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative
PE20081692A1 (es) * 2007-01-24 2008-12-18 Mochida Pharm Co Ltd Nuevo derivado de heterocicliden acetamida
US20100016285A1 (en) * 2007-01-24 2010-01-21 Mochida Pharmaceutical Co., Ltd. Heterocyclidene-n-(aryl) acetamide derivative
JP2011201776A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体
US8765815B2 (en) 2007-09-20 2014-07-01 Ramot At Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
AU2009269720A1 (en) * 2008-06-17 2012-01-19 Glenmark Pharmaceuticals S.A. Chromane derivatives as TRPV3 modulators
JP2011201777A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
JP2011201778A (ja) * 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ｐ−置換アリールアセトアミドを有するヘテロシクリデン誘導体
US8802711B2 (en) 2011-03-25 2014-08-12 Abbvie Inc. TRPV1 antagonists
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
KR102022154B1 (ko) * 2016-11-24 2019-09-18 한양대학교 산학협력단 MBD2-p66α(GATAD2A)의 상호작용을 억제하는 화합물을 포함하는 암 전이 억제 및 암 질환 예방 및 치료용 조성물
CN110149795B (zh) 2016-12-02 2023-10-03 西姆莱斯股份公司 化妆品混合物
JP6230743B1 (ja) * 2017-05-31 2017-11-15 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の結晶
JP7320113B2 (ja) 2019-08-23 2023-08-02 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
CN112409191A (zh) * 2019-08-23 2021-02-26 持田制药株式会社 光学活性的氨基醇的制备方法
WO2021039023A1 (ja) * 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
MX2022002017A (es) * 2019-08-23 2022-03-11 Mochida Pharm Co Ltd Metodo para producir derivado de heterociclideno acetamida.
US20220370404A1 (en) * 2019-10-04 2022-11-24 Senju Pharmaceutical Co., Ltd. Pharmaceutical drug containing heterocyclidene acetamide derivative
BR112023019820A2 (pt) * 2021-03-30 2023-11-07 Mochida Pharm Co Ltd Suspensão contendo derivado de heterociclidenoacetamida

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2618437B1 (fr) * 1987-07-23 1989-11-17 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les medicaments qui les contiennent
EP0411751A1 (en) 1989-06-06 1991-02-06 Beecham Group p.l.c. Renin inhibitory peptides
JP3061063B2 (ja) 1990-11-14 2000-07-10 サントリー株式会社 イミダゾリル基を有する縮合７員環系化合物
JPH05339223A (ja) * 1992-06-12 1993-12-21 Kyowa Hakko Kogyo Co Ltd 三環式化合物
GB9309621D0 (en) * 1993-05-11 1993-06-23 Wellcome Found Amide derivatives and their therapeutic use
AU684537B2 (en) * 1993-08-26 1997-12-18 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
DK0854867T3 (da) * 1995-09-29 2002-12-02 Glaxosmithkline Spa Tetrahydroquinoliner som NMDA-antagonister
JPH09221475A (ja) 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
GB9706294D0 (en) 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
US6120964A (en) 1999-12-15 2000-09-19 Eastman Kodak Company 2-(1,2-benzisothiazol-3(2H)-ylidene 1,1-dioxide)acetamides negative charge control agents for electrostatographic toners and developers
AU2002333233A1 (en) * 2001-07-09 2003-01-29 Pharmacia Italia Spa Interaction inhibitors of tcf-4 with beta-catenin
JP4075064B2 (ja) 2001-11-16 2008-04-16 アステラス製薬株式会社 ４，４−ジフルオロ−１，２，３，４−テトラヒドロ−５ｈ−１−ベンゾアゼピン誘導体又はその塩
JP2005518371A (ja) * 2001-12-10 2005-06-23 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療に於けるこれらの使用
AR038420A1 (es) * 2002-02-15 2005-01-12 Glaxo Group Ltd Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
WO2003099284A1 (en) * 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
CA2508618C (en) 2002-12-06 2012-02-21 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
EP1575918A2 (en) 2002-12-19 2005-09-21 Neurogen Corporation Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
WO2004069792A2 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid vr1 receptor
JP4334403B2 (ja) 2003-04-28 2009-09-30 アステラス製薬株式会社 ４，４−ジフルオロ−１，２，３，４−テトラヒドロ−５ｈ−１−ベンゾアゼピン誘導体又はその塩
KR100882154B1 (ko) 2003-04-28 2009-02-06 아스텔라스세이야쿠 가부시키가이샤 4,4-디플루오로-1,2,3,4-테트라하이드로-5ｈ-1-벤즈아제핀 유도체 또는 이의 염 및 이를 포함하는 의약 조성물
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AU2004247559B2 (en) 2003-06-12 2009-08-27 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
DK1664041T3 (da) 2003-09-22 2008-10-27 Euro Celtique Sa Phenylcarboxamidforbindelser, der er egnede til behandling af smerter
JP4833069B2 (ja) 2003-10-01 2011-12-07 ゼンション・リミテッド テトラヒドロ−ナフタレンおよび尿素誘導体
WO2005046683A1 (en) 2003-10-07 2005-05-26 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
JP2007509846A (ja) 2003-10-15 2007-04-19 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレンおよび尿素誘導体
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1725529A1 (en) 2004-01-23 2006-11-29 Amgen Inc. Bis bicyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain
WO2005095329A1 (en) 2004-03-31 2005-10-13 Pfizer Japan Inc. Substituted benzamide compounds as vr1 receptor antagonists
CA2571133C (en) * 2004-07-15 2011-04-19 Japan Tobacco Inc. Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor
JP2008515884A (ja) 2004-10-08 2008-05-15 アストラゼネカ・アクチエボラーグ 新規なヒドロキシメチルベンゾチアゾールアミド
WO2006058338A2 (en) 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
ES2255848B1 (es) 2004-12-16 2007-07-01 Consejo Superior Investig. Cientificas Derivados de isoquinolina como inhibidores de calpaina.
CA2616079C (en) 2005-07-22 2012-09-25 Mochida Pharmaceutical Co., Ltd. Novel heterocyclidene acetamide derivative
JP2011201776A (ja) 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ヘテロシクリデン−ｎ−（３，４−ジヒドロ−２（１ｈ）−キナゾリノン−５−イル）アセトアミド誘導体
PE20081692A1 (es) 2007-01-24 2008-12-18 Mochida Pharm Co Ltd Nuevo derivado de heterocicliden acetamida
US20100016285A1 (en) 2007-01-24 2010-01-21 Mochida Pharmaceutical Co., Ltd. Heterocyclidene-n-(aryl) acetamide derivative
JP2011201777A (ja) 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
JP2011201778A (ja) 2008-07-23 2011-10-13 Mochida Pharmaceut Co Ltd ｐ−置換アリールアセトアミドを有するヘテロシクリデン誘導体
JP2012006837A (ja) 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体

Also Published As

Publication number Publication date
AU2006271297B2 (en) 2012-02-02
US20110112071A1 (en) 2011-05-12
JP5303590B2 (ja) 2013-10-02
KR20110093948A (ko) 2011-08-18
JP4754566B2 (ja) 2011-08-24
JP2011153146A (ja) 2011-08-11
NZ565080A (en) 2011-03-31
AU2006271297C1 (en) 2012-06-14
CR9660A (es) 2008-05-22
CA2616079C (en) 2012-09-25
EP1908753B1 (en) 2014-12-17
US7910751B2 (en) 2011-03-22
NO20080917L (no) 2008-04-22
BRPI0613771B1 (pt) 2021-11-23
JPWO2007010383A1 (ja) 2009-01-29
ECSP088129A (es) 2008-04-28
NO341962B1 (no) 2018-03-05
ES2531621T3 (es) 2015-03-18
EP1908753A4 (en) 2009-11-11
AU2006271297A1 (en) 2007-01-25
KR20080031971A (ko) 2008-04-11
PT1908753E (pt) 2015-02-06
US8383839B2 (en) 2013-02-26
US20080287428A1 (en) 2008-11-20
WO2007010383A1 (ja) 2007-01-25
KR101136183B1 (ko) 2012-04-17
CA2616079A1 (en) 2007-01-25
EP1908753A1 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
BRPI0613771A2 (pt) derivado de heterociclideno acetamida
AR065014A1 (es) Derivado de heterocicliden-n-(aril)acetamida
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
AR057023A1 (es) Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
BRPI0512676A (pt) derivados de indolil alquil amina substituìdos como inibidores de histona desacetilase
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
RS53588B1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
ATE503746T1 (de) Neue imidazolidinderivate
BRPI0513863A (pt) derivados de uréia cìclica substituìda por heterociclo, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
EA200701121A1 (ru) Потенциаторы рецепторов глутамата
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
BRPI0014901B8 (pt) composto derivado de trifenil-alquenos e composição farmacêutica para uso como moduladores de receptores seletivos de estrogênios
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
CO5690607A2 (es) Compuestos de piridina como inhibidores de dipeptidil peptidasa iv
CO6251248A2 (es) Compuestos de tiazolopiridina como moduladores de sirtuina
EA200602170A1 (ru) Производные пиперидина, композиции на их основе, способы их применения
BRPI0510305A (pt) composto ou um sal do mesmo, pródroga ou um sal da mesma, agente farmacêutico, método de produção do composto ou um sal do mesmo, inibidor de metaloproteinase de matriz ou um sal do mesmo ou uma pródroga do mesmo, método de inibir uma metaloproteinase de matriz, e, uso de um composto ou de um sal do mesmo ou de uma pródroga do mesmo
BRPI0615248A2 (pt) derivado tendo atividade agonista de ppar
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
BR0314363A (pt) Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6
AR042064A1 (es) Compuestos de amina con actividad inhibidora de la union al receptor de somastotina
ATE427310T1 (de) Kondensierte bicyclische pyrimidinderivate
BRPI0407386A (pt) Derivados de álcool de amino, composições farmacêuticas contendo os mesmos e uso destes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/07/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.